Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Net Cash Flow (2020 - 2025)

HCW Biologics (HCWB) has disclosed Net Cash Flow for 6 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 722.88% year-over-year to -$1.3 million, compared with a TTM value of $98688.0 through Sep 2025, up 100.97%, and an annual FY2024 reading of $1.1 million, up 105.76% over the prior year.
  • Net Cash Flow was -$1.3 million for Q3 2025 at HCW Biologics, down from $1.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $95.1 million in Q4 2021 and bottomed at -$88.5 million in Q3 2021.
  • Average Net Cash Flow over 5 years is -$387311.8, with a median of -$1.6 million recorded in 2021.
  • Peak annual rise in Net Cash Flow hit 4721.66% in 2021, while the deepest fall reached 2768.75% in 2021.
  • Year by year, Net Cash Flow stood at $95.1 million in 2021, then crashed by 104.1% to -$3.9 million in 2022, then tumbled by 95.64% to -$7.6 million in 2023, then soared by 148.21% to $3.7 million in 2024, then tumbled by 136.51% to -$1.3 million in 2025.
  • Business Quant data shows Net Cash Flow for HCWB at -$1.3 million in Q3 2025, $1.3 million in Q2 2025, and -$3.6 million in Q1 2025.